Telmisartan in Prostate Cancer

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Tyler J Curiel
Study ID
NCT06168487
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Telmisartan — DRUG
    Patients will be given telmisartan alone or with standard of care chemotherapy.
  • Standard of Care Regimen — OTHER
    Standard of Care Regimen

Study Details

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.

Key Dates

Start date
Apr 22, 2024
Status verified
Aug 2025
Primary completion
Apr 1, 2026
Completion
Apr 1, 2027

Study Design

Enrollment
36 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Cohort 1: Telmisartan Alone
    Patients will receive telmisartan alone.
  • Experimental: Cohort 2: Telmisartan + Standard of Care Regimen
    Patients will receive telmisartan with cabazitaxel or docetaxel without abiraterone), or telmisartan with docetaxal with abirateron or olaparib or rucaparib, or talazoparib plus enzalutamide.

Primary Outcome Measure

Tolerability of oral telmisartan [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dartmouth HealthLebanonNew Hampshire03756
Rodwell Mabaera, MD
Rodwell Mabaera, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lebanon, NH

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Dartmouth Health· Lebanon, NH

Related Studies